Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An oligoastrocytoma characterized by the presence of increased cellularity, nuclear atypia, pleomorphism, and high mitotic activity.
Biomarker and diagnostic research for anaplastic oligoastrocytoma has been reported in the published literature.
4 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
108 publications have been identified in PubMed for anaplastic oligoastrocytoma. Research spans Basic Science / Preclinical (21%), Epidemiology / Natural History (20%), and Diagnostic / Biomarker (19%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 23 |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 4:30 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
21%
Disease patterns and progression | 22 | 20% |
Testing and diagnosis research | 21 | 19% |
Clinical study results | 21 | 19% |
Research summaries | 15 | 14% |
Patient case studies | 4 | 4% |
New treatment approaches | 2 | 2% |
Langegård UE (2026). [PMID: 42190579](https://pubmed.ncbi.nlm.nih.gov/42190579/). *Eur J Oncol Nurs*. [Epidemiology / Natural History]
Zhao H (2026). [PMID: 42061048](https://pubmed.ncbi.nlm.nih.gov/42061048/). *Neuroimage Clin*. [Basic Science / Preclinical]
Guo C (2026). [PMID: 41496589](https://pubmed.ncbi.nlm.nih.gov/41496589/). *Nucl Med Commun*. [Diagnostic / Biomarker]
Kang MS (2026). [PMID: 42005492](https://pubmed.ncbi.nlm.nih.gov/42005492/). *J Pharm Bioallied Sci*. [Clinical Trial Publication]
Sill M (2026). [PMID: 41349541](https://pubmed.ncbi.nlm.nih.gov/41349541/). *Cancer Cell*. [Diagnostic / Biomarker]
Yao J (2026). [PMID: 42131760](https://pubmed.ncbi.nlm.nih.gov/42131760/). *Neurooncol Pract*. [Clinical Trial Publication]
Eddy EM (2026). [PMID: 41610383](https://pubmed.ncbi.nlm.nih.gov/41610383/). *Neurol Neuroimmunol Neuroinflamm*. [Basic Science / Preclinical]
Colman H (2026). [PMID: 41325560](https://pubmed.ncbi.nlm.nih.gov/41325560/). *J Clin Oncol*. [Clinical Trial Publication]
Nowacka A (2026). [PMID: 41753119](https://pubmed.ncbi.nlm.nih.gov/41753119/). *J Clin Med*. [Review / Meta-Analysis]
Li J (2026). [PMID: 41271174](https://pubmed.ncbi.nlm.nih.gov/41271174/). *Radiother Oncol*. [Diagnostic / Biomarker]